Ondine Biomedical Inc. (LON:OBI – Get Free Report) insider Carolyn Cross purchased 200,775 shares of the stock in a transaction dated Thursday, January 30th. The shares were purchased at an average cost of GBX 12 ($0.15) per share, for a total transaction of £24,093 ($29,921.76).
Ondine Biomedical Price Performance
Shares of OBI stock opened at GBX 12.85 ($0.16) on Friday. The firm’s 50-day moving average is GBX 9.08 and its two-hundred day moving average is GBX 7.95. Ondine Biomedical Inc. has a 12 month low of GBX 4.50 ($0.06) and a 12 month high of GBX 13.30 ($0.17). The company has a debt-to-equity ratio of 1,847.37, a current ratio of 0.80 and a quick ratio of 8.26. The company has a market capitalization of £35.63 million, a PE ratio of -428.33 and a beta of 0.10.
About Ondine Biomedical
Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings.
Read More
- Five stocks we like better than Ondine Biomedical
- Expert Stock Trading Psychology Tips
- Starbucks’ CEO-Led Turnaround Gains Traction: New Highs Likely
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- 3 Chemical Stocks Defying Tariff Worries With Growth Potential
- Stock Average Calculator
- How Growth Investors Find High-Growth Stocks and Maximize Returns
Receive News & Ratings for Ondine Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ondine Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.